{"filings":[{"id":443198,"accession_number":"0001104659-26-061208","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2026-05-14T20:23:01+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech Q1 net income $108.4M; PRV sale for $205M and ZYCUBO approval drive results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $108.4M ($3.44 basic EPS) vs net loss $12.7M in Q1 2025; revenue $16.0M up from $13.1M.","Subsidiary Cyprium sold Rare Pediatric Disease PRV for $205M in March 2026; ZYCUBO approved for Menkes disease.","Debt reduced: prepaid Oaktree loan to $15M outstanding; cash increased to $255.8M from $79.4M.","Checkpoint acquisition by Sun Pharma gives Fortress ~$28M upfront + 2.5% royalty on UNLOXCYT sales.","Journey Medical's Emrosi launched; payer access expanded to 85% of US commercial lives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103958,"accession_number":"0001104659-26-037749","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech reports 2025 results; ZYCUBO approved, PRV sold for $205M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ZYCUBO FDA-approved for Menkes disease; Cyprium sold PRV for $205M gross, with potential $128M in sales milestones.","Checkpoint acquired by Sun Pharma; Fortress received ~$28M upfront, up to $4.8M CVR, and 2.5% royalty on UNLOXCYT.","Consolidated net loss attributable to common stockholders improved to $(1.9)M ($(0.07)/share) vs $(55.9)M ($(2.69)/share) in 2024.","Revenue rose to $63.3M in 2025 from $57.7M in 2024, driven by Journey Medical's Emrosi and dermatology portfolio.","Prepaid Oaktree loan to $15.0M outstanding; cash at $79.4M as of year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103957,"accession_number":"0001104659-26-036818","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fortress Biotech subsidiary Cyprium closes PRV sale for $205M; Fortress expects over $100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cyprium sold Rare Pediatric Disease Priority Review Voucher for $205M gross proceeds.","Fortress (80.4% owner) expects over $100M from dividends and intercompany agreements.","PRV was issued upon FDA approval of ZYCUBO (copper histidinate) on Jan 12, 2026.","Cyprium redeemed all outstanding 9.375% Perpetual Preferred Stock in connection with sale.","Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to ~$128M in milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103956,"accession_number":"0001104659-26-018371","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Cyprium (Fortress subsidiary) sells PRV for $205M cash; Oaktree loan covenants eased","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cyprium Therapeutics, 80.4% owned by Fortress, agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205M cash.","Fortress expects to receive at least $100M from Cyprium via dividends and intercompany payments after closing.","Second Amendment to Oaktree loan: mandatory $10M prepayment upon PRV proceeds; if loan ≤$10M, key financial covenants removed.","PRV issued after FDA approval of ZYCUBO (copper histidinate) for Menkes disease in Jan 2026; 20% of proceeds owed to NIH.","Cyprium still eligible for up to $129M in development/sales milestones and royalties from Sentynl on ZYCUBO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103955,"accession_number":"0001104659-26-003121","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves ZYCUBO for Menkes disease; Cyprium gets PRV, up to $129M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved ZYCUBO (copper histidinate) as first and only U.S. treatment for Menkes disease in pediatric patients.","Rare Pediatric Disease PRV issued at approval and will be transferred to Cyprium, a majority-owned Fortress subsidiary.","Cyprium eligible for tiered royalties on net sales and up to $129M in aggregate development and sales milestones from Sentynl.","Early ZYCUBO treatment showed median overall survival of 177.1 months vs 17.6 months in external control (≈80% risk reduction).","Fortress notes three FDA approvals in 15 months (Emrosi, UNLOXCYT, ZYCUBO) and recent $28M upfront from Checkpoint sale to Sun Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120231,"accession_number":"0001104659-25-121187","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"Fortress Biotech amends credit agreement with Oaktree; extends maturity to June 2028, issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from July 2027 to June 30, 2028; $29.5M outstanding on $35M initial borrowing.","Principal repayment schedule set: 12.5% due Sep 30, 2027, 12.5% Dec 31, 2027, 37.5% Mar 31, 2028, 37.5% at maturity.","Journey Medical minimum net sales covenant raised: $60M (Dec 2025) to $80M (Dec 2026 and quarterly thereafter).","Warrants issued to lenders for 600k shares at $2.62/share, exercisable immediately, expiring July 25, 2031.","Covenant threshold: Minimum Net Sales Test waived if outstanding principal ≤ $10M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120230,"accession_number":"0001104659-25-120893","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts CUTX-101 NDA resubmission as Class 1; PDUFA date Jan 14, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA resubmission for CUTX-101 (copper histidinate) for Menkes disease; new PDUFA target action date January 14, 2026.","Prior complete response letter in Sept 2025 cited only cGMP manufacturing observations; no efficacy/safety deficiencies.","Sentynl (Zydus unit) leads development/commercialization; Cyprium eligible for up to $129M milestones plus PRV if approved.","CUTX-101 previously granted Priority Review; early treatment showed significant improvement in overall survival."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120229,"accession_number":"0001104659-25-112945","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fortress Biotech's majority-owned Cyprium gets NDA resubmission for CUTX-101 to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Sentynl resubmitted NDA for CUTX-101 to FDA on Nov 14, 2025.","Prior Complete Response Letter on Oct 1, 2025.","Cyprium retains ownership of any Priority Review Voucher upon approval.","Cyprium eligible for up to $129M in development and sales milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120228,"accession_number":"0001104659-25-111979","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech Q3 net revenue up 20.5% to $17.6M; net income $3.7M vs prior loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $17.6M (Q3 2025) vs $14.6M (Q3 2024), driven by dermatology product sales.","Net income attributable to common stockholders $3.7M ($0.13 basic EPS) vs net loss of $15.0M in Q3 2024.","Cash and equivalents $86.2M as of Sep 30, 2025, up from $57.3M at Dec 31, 2024.","Checkpoint sale to Sun Pharma closed May 2025; Fortress received ~$28M upfront plus up to $4.8M CVR and 2.5% royalty on UNLOXCYT sales.","Dotinurad Phase 3 trials dosed Oct 2025; Crystalys raised $205M Series A; Urica (Fortress sub) holds equity and 3% royalty."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":47183000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120227,"accession_number":"0001104659-25-095366","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Fortress Biotech's CUTX-101 over manufacturing issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued CRL for CUTX-101 NDA to treat Menkes disease; cGMP deficiencies at the manufacturing facility.","No efficacy/safety deficiencies cited; CRL solely based on manufacturing observations at the facility.","Partner Sentynl expects to request FDA meeting and pursue resubmission promptly after facility's recent response.","Cyprium eligible for up to $129M in milestones plus a Rare Pediatric Disease PRV upon NDA approval.","NDA initially granted Priority Review; early treatment showed significant survival improvement in trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136806,"accession_number":"0001558370-25-011561","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech posts Q2 net income $13.4M; Checkpoint acquisition yields $28M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Checkpoint acquired by Sun Pharma in May; Fortress received ~$28M at close, up to $4.8M CVR, plus 2.5% royalty on UNLOXCYT sales.","FDA accepted CUTX-101 NDA for priority review; PDUFA goal date September 30, 2025.","Q2 consolidated net revenue $16.4M ($15.0M from dermatology); net income $13.4M vs net loss $13.3M a year ago.","Consolidated cash $74.4M as of June 30, up from $57.3M at Dec 31, 2024, boosted by Checkpoint proceeds.","Emrosi commercial launch underway; payer coverage expanded to 100M U.S. commercial lives as of July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":29552000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136805,"accession_number":"0001558370-25-009264","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fortress' former asset anselamimab fails primary endpoint in Phase III CARES study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AstraZeneca announced anselamimab did not achieve statistical significance on primary endpoint (ACM + CVH hierarchy) in Mayo stages IIIa/IIIb AL amyloidosis.","Prespecified subgroup showed 'highly clinically meaningful improvement' in ACM and CVH; AZ plans further evaluation and regulatory discussions.","Fortress remains eligible for up to ~$125M in milestones from the 2021 Caelum sale; outcome reduces likelihood of near-term payments.","Anselamimab was well-tolerated; detailed results to be presented at future medical meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154037,"accession_number":"0001558370-25-008787","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fortress Biotech stockholders elect seven directors, approve charter amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: Rosenwald, Harvey, Hoenlein, Klein, Lobell, Lorenz, Weiss.","Ratification of KPMG LLP as independent auditor for FY2025 approved: 20,400,173 for, 314,490 against.","Advisory vote on executive compensation passed: 9,388,005 for, 312,265 against, 10,917,039 broker non-votes.","Board sets say-on-pay frequency every three years until 2031; vote: 2,051,405 for one year, 7,421,176 for three years.","Charter amendment for officer exculpation approved: 7,964,484 for, 1,723,623 against, 10,917,039 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154036,"accession_number":"0001558370-25-008433","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Fortress closes sale of Checkpoint to Sun Pharma; receives ~$28M cash plus milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Checkpoint merged into Sun Pharma on May 30, 2025; deconsolidated from Fortress.","Fortress gets ~$28.0M cash at close, up to $4.8M regulatory milestone, and quarterly royalty of 2.5% on certain product net sales.","Pro forma gain on deconsolidation is $26.6M; pro forma net loss attributable to common stockholders improves from $(0.48) to $0.57 per share for Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154035,"accession_number":"0001558370-25-007878","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech Q1 net loss narrows to $12.7M; Checkpoint acquisition on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated net loss $12.7M ($0.48/sh) vs $17.9M ($1.04/sh) in Q1 2024.","Cash $91.3M as of March 31, 2025, up $34.0M from Dec 2024; Checkpoint holds $33.0M.","Emrosi launched in March 2025; first prescriptions filled for inflammatory rosacea lesions.","Checkpoint to be acquired by Sun Pharma for $4.10/sh plus $0.70 CVR; Fortress expects ~$28M at closing.","CUTX-101 NDA priority review with PDUFA Sept 30, 2025; Cyprium retains 100% of any PRV."],"consensus_eps_estimate":-0.5049,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":13139000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154034,"accession_number":"0001558370-25-004898","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fortress Biotech director Lucy Lu resigns from board, to become Chief Strategy Officer on April 21","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucy Lu resigned from the Board of Directors effective April 15, 2025, with no disagreement with the Company.","She accepted an offer to join Fortress Biotech as Chief Strategy Officer effective April 21, 2025.","Dr. Lu will transition from board oversight to an executive leadership role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172667,"accession_number":"0001558370-25-004154","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech posts FY2024 net loss of $55.9M; Checkpoint to be acquired by Sun Pharma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders of $55.9M ($2.69/sh) vs $68.7M ($8.47/sh) in FY2023; net revenue $57.7M, down from $84.5M.","FDA approved Emrosi (rosacea) in Nov 2024 and UNLOXCYT (cSCC) in Dec 2024; commercial launch of Emrosi underway.","Checkpoint to be acquired by Sun Pharma for $4.10/sh upfront plus up to $0.70 CVR; Fortress expects ~$28M at closing plus 2.5% royalty.","FDA accepted CUTX-101 NDA for priority review with PDUFA date Sept 30, 2025.","Cash $57.3M as of Dec 31, 2024; paused Series A Preferred dividends in July 2024, deferring ~$0.7M/month."],"consensus_eps_estimate":-0.5049,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":13139000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172666,"accession_number":"0001558370-25-002541","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Fortress Biotech subsidiary Checkpoint to be acquired by Sun Pharma for $4.10/share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sun Pharma to acquire Checkpoint at $4.10 per share in cash plus non-tradable CVR for up to $0.70 based on EU regulatory milestones for cosibelimab.","Fortress, owning ~11.2% of Checkpoint shares and controlling majority voting power, agrees to vote in favor and forgo certain payments.","Fortress will receive a 2.5% royalty on worldwide net sales of certain Checkpoint/Sun Pharma products post-closing.","Deal expected to close by Sept 5, 2025, subject to stockholder and antitrust approvals; termination fee of $12.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172665,"accession_number":"0001558370-25-000247","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA extends PDUFA date for Fortress subsidiary's NDA for CUTX-101 to Sep 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended target action date for CUTX-101 (Copper Histidinate) NDA to September 30, 2025.","Sentynl assumed full responsibility for CUTX-101 development and commercialization in Dec 2023.","Cyprium retains ownership of any Priority Review Voucher; eligible for up to $129M milestones plus royalties.","Fortress owns approximately 76% of Cyprium Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172664,"accession_number":"0001558370-25-000025","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts Cyprium's NDA for CUTX-101 for priority review; action date June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA granted priority review to CUTX-101 (Copper Histidinate) NDA for treating Menkes disease.","Target PDUFA action date is June 30, 2025; Sentynl (Zydus Group) will commercialize upon approval.","Cyprium retains any Priority Review Voucher and is eligible for up to $129M in milestones plus royalties.","Fortress Biotech owns ~76% of Cyprium, founded in 2017."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189675,"accession_number":"0001558370-24-016294","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Fortress subsidiary Checkpoint's UNLOXCYT for advanced cSCC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved UNLOXCYT (cosibelimab-ipdl) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) in adults not candidates for curative surgery/radiation.","UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.","Approval based on objective response rates and duration of response from Study CK-301-101 (NCT03212404).","Checkpoint Therapeutics is a majority-controlled subsidiary of Fortress Biotech, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189674,"accession_number":"0001558370-24-015726","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech Q3 net loss $15M; FDA approved Emrosi on Nov 4; cosibelimab PDUFA Dec 28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders $15.0M ($0.76/shr) vs $7.1M loss in Q3 2023.","Consolidated net revenue $14.6M (all from dermatology products); Q3 2023 revenue $34.8M included $19M license fee.","Cash and equivalents $58.9M as of Sep 30, 2024, down $22M YTD; included $25.6M at Fortress and private subs.","Paused Series A preferred dividends in July 2024, deferring ~$0.7M cash/month; new $35M Oaktree loan terms.","FDA approval of Emrosi on Nov 4; cosibelimab PDUFA date Dec 28; Checkpoint raised $9.2M in Nov warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":42555000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189673,"accession_number":"0001558370-24-014186","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fortress Biotech subsidiary Journey Medical receives FDA approval for Emrosi to treat rosacea in adults","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Emrosi (Minocycline HCL ER 40mg) for inflammatory lesions of rosacea; Journey Medical to market it in U.S.","Phase 3 trials met all endpoints; Emrosi showed statistically significant superiority over Oracea® 40mg and placebo.","Initial supply expected late Q1 or early Q2 2025; developed with Dr. Reddy’s Laboratories.","Journey Medical is a majority-controlled subsidiary of Fortress Biotech (FBIO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206167,"accession_number":"0001104659-24-102033","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Fortress Biotech raises $8M in registered direct offering and private placements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $8M gross from sale of 3,939,394 shares at $1.65 and warrants to institutional investors; CEO also purchased shares/warrants.","Private placement warrants exercisable at $1.84, six months post-issuance, 5.5-year term.","CEO Lindsay Rosenwald purchased 763,359 shares at $1.84 and warrants at $0.125 per warrant.","Proceeds for R&D, clinical trials, working capital; lock-up agreements for insiders for 60 days after effective date.","A.G.P./Alliance Global Partners acted as placement agent with 7% commission (3.5% for insider)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206166,"accession_number":"0001558370-24-012057","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech Q2 net loss $13.3M; pauses preferred dividend; two PDUFA dates in Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net revenue $14.9M (dermatology) vs $17.4M Q2 2023; net loss attributable to common $13.3M ($0.73/sh) vs $26.9M ($3.65/sh).","Cash and equivalents $76.2M at June 30, down from $80.9M at Dec 31, 2023; $38.2M attributable to Fortress/private subs.","Board paused Series A Preferred Stock (9.375%) dividends indefinitely, deferring ~$0.7M/month; new Oaktree loan $35M (up to $50M) repaid prior $50M, net paydown $15M.","FDA PDUFA goal dates: DFD-29 for rosacea Nov 4, 2024; cosibelimab for cSCC Dec 28, 2024 – potential approvals in Q4.","Subsidiary Urica transferred dotinurad rights to Crystalys for 35% equity and 3% royalty; clinical trials ongoing for AJ201 (SBMA) and Triplex (CMV)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":27926000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206165,"accession_number":"0001558370-24-010208","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Fortress Biotech enters $50M Oaktree loan, repays prior $50M, extends maturity to 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $35M initially under new $50M senior secured credit agreement with Oaktree; eligible for additional $15M at lenders' discretion.","Interest rate of 3-month SOFR + 7.625% (2.50% floor, 5.75% cap); 30-month interest-only period, maturity July 25, 2027.","Repaid and terminated existing $50M loan due August 2025; issued warrants to purchase 506,390 shares at $2.0735 per share.","Covenants include minimum liquidity of $7M and Journey Medical minimum net sales of $50M trailing 12 months, tested quarterly.","Company cites potential for up to three regulatory approvals on NDAs/BLAs in next 12 months and possible fourth BLA filing in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206164,"accession_number":"0001558370-24-009903","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Fortress Biotech's Urica sells gout drug dotinurad to Crystalys for 35% equity and 3% royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Urica sold its URAT1 inhibitor dotinurad (gout treatment) and related IP to Crystalys Therapeutics.","Urica received 35% of Crystalys' outstanding equity; cannot be diluted below 15% until Crystalys raises $150M in equity.","Urica gets a securitized 3% royalty on future net sales of dotinurad plus nominal cost reimbursements.","Urica has the right to appoint one director and one board observer to Crystalys' board.","Crystalys must use commercially reasonable efforts to develop and commercialize dotinurad."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206163,"accession_number":"0001558370-24-009677","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fortress Biotech pauses monthly dividend on Series A Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.1953125/share on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock paused effective July 1, 2024; no payment on July 31, 2024.","Pause defers approximately $0.7 million in cash dividend payments per month; dividends continue to accrue and cumulate.","Board will reassess regularly based on profitability and cash flow; cited upcoming potential regulatory approvals (DFD-29, cosibelimab, CUTX-101, and CAEL-101) as inflection points.","CEO Lindsay Rosenwald noted the pause aims to maintain financial flexibility ahead of up to four potential NDA/BLA submissions or approvals in the next 12-18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223218,"accession_number":"0001558370-24-009624","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Fortress Biotech issues 2.03M shares of common stock to settle Urica Preferred Stock obligations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,028,345 shares of common stock to former holders of Urica Preferred Stock.","Satisfied cumulative dividends and mandatory tender under Dividend Agreement dated Dec 27, 2022.","Fortress elected shares instead of cash; paid $20,747.62 for fractional shares and unpaid dividends.","Shares issued under Section 4(a)(2) exemption; resale registered effective June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223217,"accession_number":"0001558370-24-009466","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Fortress Biotech adopts bylaw amendments on director voting and exclusive forum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director election voting changed to majority of votes cast in uncontested elections, plurality in contested.","Directors failing to receive majority vote must promptly tender resignation; board may accept or reject.","Delaware designated as exclusive forum for certain disputes under the amended bylaws.","Amendments effective June 19, 2024, adopted by Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223216,"accession_number":"0001104659-24-066162","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Fortress Biotech shareholders approve director slate, KPMG ratification, and equity plan share increases","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all 8 directors; Rosenwald received 7.88M for, 279K against; broker non-votes 6.1M.","Ratified KPMG as auditor for FY2024 with 13.93M for, 325K against.","Approved Incentive Plan amendment adding 10M shares and raising annual option/SAR limit to 1M shares.","Approved ESPP amendment adding 1M shares and raising Offering limit to 5,000 shares.","Approved LTIP amendment extending term to July 15, 2035 with related changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223215,"accession_number":"0001104659-24-061958","cik":1429260,"company_name":"Fortress Biotech, Inc.","ticker":"FBIO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fortress Biotech Q1 net loss narrows to $17.7M; FDA accepts DFD-29 NDA for rosacea","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated net revenue $13.0M, all from dermatology products, up 7% YoY driven by Qbrexza and Accutane.","Net loss attributable to common stockholders $(17.7)M ($1.03/share) vs $(23.5)M ($3.47/share) in Q1 2023.","Cash and equivalents $85.8M as of March 31, up from $83.4M; includes $11M January direct offering.","FDA accepted DFD-29 NDA with PDUFA date Nov 4, 2024; potential only oral therapy for rosacea lesions and erythema.","Triplex CMV vaccine Phase 2 for HIV/CMV fully enrolled; topline data Q4 2024; liver transplant trial dosed first patient."],"consensus_eps_estimate":-0.5049,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":13030000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91684635.97026022,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}